United States-based OTITOPIC has added a new indication for treatment of lung cancer for its Aspirin inhalation product, it was reported yesterday.
The product when inhaled in Dry Powder formulation directly into the deep sites of the lung is a novel new approach to lung cancer treatment. The company says that treatment can potentially provide benefits superior to other common therapies, greatly improving clinical results for patients being treated for lung cancer.
The product has been demonstrated to have extensive pharmacological activities including anti-inflammation, anticancer and pain-relieving activities. It also inhibits platelets and has blood thinning properties which are beneficial in preventing and treating heart attacks.
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Genprex increases sites for Acclaim-3 clinical trial
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib